Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015
Standard
Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015. / Rotermund, Roman; Mader, Marius M; Burkhardt, Till; Matschke, Jakob; Aberle, Jens; Krajewski, Kara; Flitsch, Jörg; Rahvar, Amir-Hossein.
in: NEUROSURG FOCUS, Jahrgang 48, Nr. 6, 06.2020, S. E9.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015
AU - Rotermund, Roman
AU - Mader, Marius M
AU - Burkhardt, Till
AU - Matschke, Jakob
AU - Aberle, Jens
AU - Krajewski, Kara
AU - Flitsch, Jörg
AU - Rahvar, Amir-Hossein
PY - 2020/6
Y1 - 2020/6
N2 - OBJECTIVE: The purpose of this study was to analyze the clinical and biochemical outcome of consecutive patients with acromegaly after microscopic transsphenoidal surgery (MTS) at a single center over an 8-year period.METHODS: A retrospective analysis of patients with acromegaly treated via MTS between 2008 and 2015 at the authors' center was performed. The mean follow-up was 29 months (range 1-120 months). Parameters investigated included tumor size, pre- and postoperative insulin-like growth factor-I, growth hormone levels, pretreatment, perioperative complications, and clinical outcome.RESULTS: A total of 280 patients with acromegaly were treated surgically at the authors' center over the abovementioned time frame and were included in analyses. For 231 of these patients, complete follow-up data were available for evaluation. One hundred eighty-eight patients (81%) showed remission initially according to current criteria. So far, 23 of these patients relapsed in the further course, so that on follow-up 165 patients (71%) demonstrated full remission by surgery alone. Most patients in whom remission after surgery failed were treated with somatostatin receptor ligands and/or dopamine agonists as second-line treatment. The main postoperative complications included transient hyponatremia and diabetes insipidus (13/280; 4.6%). CSF leakage only occurred in 2 cases (2/280; 0.7%). No surgery-related death occurred.CONCLUSIONS: The data underline the effectiveness of MTS in acromegaly. Many patients with recurrent disease or incomplete tumor resection can be successfully managed pharmacologically.
AB - OBJECTIVE: The purpose of this study was to analyze the clinical and biochemical outcome of consecutive patients with acromegaly after microscopic transsphenoidal surgery (MTS) at a single center over an 8-year period.METHODS: A retrospective analysis of patients with acromegaly treated via MTS between 2008 and 2015 at the authors' center was performed. The mean follow-up was 29 months (range 1-120 months). Parameters investigated included tumor size, pre- and postoperative insulin-like growth factor-I, growth hormone levels, pretreatment, perioperative complications, and clinical outcome.RESULTS: A total of 280 patients with acromegaly were treated surgically at the authors' center over the abovementioned time frame and were included in analyses. For 231 of these patients, complete follow-up data were available for evaluation. One hundred eighty-eight patients (81%) showed remission initially according to current criteria. So far, 23 of these patients relapsed in the further course, so that on follow-up 165 patients (71%) demonstrated full remission by surgery alone. Most patients in whom remission after surgery failed were treated with somatostatin receptor ligands and/or dopamine agonists as second-line treatment. The main postoperative complications included transient hyponatremia and diabetes insipidus (13/280; 4.6%). CSF leakage only occurred in 2 cases (2/280; 0.7%). No surgery-related death occurred.CONCLUSIONS: The data underline the effectiveness of MTS in acromegaly. Many patients with recurrent disease or incomplete tumor resection can be successfully managed pharmacologically.
U2 - 10.3171/2020.3.FOCUS2061
DO - 10.3171/2020.3.FOCUS2061
M3 - SCORING: Journal article
C2 - 32480363
VL - 48
SP - E9
JO - NEUROSURG FOCUS
JF - NEUROSURG FOCUS
SN - 1092-0684
IS - 6
ER -